Search results
Results from the WOW.Com Content Network
The gene sequencing machine maker founded Grail and spun it off in 2016, but re-acquired it in 2021 for $7.1 billion to enter the cancer early-detection market. Illumina's board approves to spin ...
(Reuters) -Shares of Grail fell as much as 13.7% in their market debut on Tuesday after being spun out of gene-sequencing company Illumina. The stock traded as low as $15.84 after opening at $18. ...
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California. ... [23] [24] [25] The spinoff was completed in June 2024, ...
The blood test, called Galleri, can detect multiple types of cancer early and targets 80% of cancers currently not screened for that result in cancer deaths, Grail CEO Bob Ragu
Illumina, Inc. is an American biotechnology company, ... In June 2024 Illumina has completed the spin-off of Grail, keeping only a minority stake of 14.5%. [50]
Rastetter served on the board (2016-2020) of GRAIL, Inc., a life sciences company in Menlo Park, California that focuses on early cancer detection using deep genome sequencing; the company was a spinoff of Illumina and Google.
In April 2024, the EC approved Illumina's plan, allowing Illumina to explore either a trade sale or a capital markets transaction (spin-off) to divest Grail. In May 2024, Illumina publicly filed a Form 10 registration statement with the U.S. SEC, a necessary step for a potential capital markets separation of Grail.
The spin-off of the Advanced Materials company is expected to be completed by the end of 2025 or early in 2026. What will the new companies do? Here's what the three new companies will do: